Rallybio (RLYB) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Rallybio Corporation  (NASDAQ: RLYB)


Rallybio's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Rallybio's ROA in the second quarter of 2026?
Rallybio Corporation achieved a return on average assets (ROA) of 64.12 % in its second quarter of 2026, this is above RLYB's average return on assets of -40.57%.
Rallybio Corporation assets over the 12 months ending in its second quarter of 2026 are valued at $71 million

ROA has improved compared to -13.25% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 16 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3309, from total ROA ranking in the first quarter of 2026 at 3920.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 93.47 % -6.56 % -8.38 % -14.62 % -44.39 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 46 -8 -9 -14 -42
Return On Assets (TTM) 64.12 % -13.25 % -14.98 % -23.09 % -64.81 %
RLYB's Total Ranking # 3309 # 3920 # 3611 # 4236 # 4311
Total Assets (TTM) in million 100 54 62 68 52
Seq. Total Assets Change 83.19 % -12.51 % -7.97 % 31.17 % -11.52 %
Seq. Net Income Change - - - - -

RLYB's 5 Years Annual ROA >> Back to RLYB Management Effectiveness >> Compare RLYB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 8
Sector # 17
Overall # 52

Return On Assets Statistics
High Average Low
64.51 %
-40.57 %
-69.33 %
(Jun 30 2026)   (Sep 30 2024)



  News about Rallybio Corporation Return on Assets ROA

Advancing the Frontiers of Fetal and Neonatal Alloimmune Thrombocytopenia Prevention Rallybios RLYB212 Clinical Tria...

Rallybio Corporation, a clinical-stage biotechnology company, has embarked on a transformative journey to address the challenges posed by fetal and neonatal alloimmune thrombocytopenia (FNAIT). This article provides insights into the recent initiation of a Phase 2 clinical trial for RLYB212, a novel monoclonal anti-HPA-1a antibody, alongside an epidemiological analysis highlighting the susceptibility of diverse populations to FNAIT. The implications of these developments for maternal and fetal health are profound, with the potential to revolutionize the management of alloimmunization risks in pregnant women.Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a serious condition that can arise when a pregnant woman develops antibodies against her fetus s platelets. The most common cause is the incompatibility of the human platelet antigen HPA-1a. Historically, management of FNAIT has been limited, leading to grave outcomes for affected neonates. Rallybio Corporation aims to close this therapeutic gap with RLYB212, a monoclonal antibody designed to mitigate the risks of maternal alloimmunization and subsequent FNAIT.



Financial Statements
Rallybio's Assets $ 100 million RLYB's Balance sheet
Rallybio's Income $ 44 million Quarterly RLYB's Income Statement
RLYB's Income by Division See RLYB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -8.38 % -41.17 % -35.81 % -1.23 % -
Total Assets in million 62 68 116 180 182
Y / Y Net Income Change - - - - -
Net Income in million -9 -58 -75 -67 0
Annual Return On Assets -14.42 % -85.02 % -64.55 % -37.04 % 0 %

RLYB's 5 Years Annual ROA >> Back to RLYB Management Effectiveness >> Compare RLYB ROA to its Competitors



More Return On Assets Ratios
RLYB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RLYB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RLYB's Competitors
Subscribers only: Roa for Rallybio's Suppliers
Subscribers only: Return On Assets for RLYB's Customers

You may also want to know
RLYB's Roi RLYB's Inventory Turnover Ratio RLYB's Growth Rates RLYB's Dividend Comparisons
RLYB's Profitability Ratios RLYB's Asset Turnover Ratio RLYB's Dividend Growth
RLYB's Roe RLYB's Valuation Ratios RLYB's Financial Strength Ratios RLYB's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Kyntra Bio Inc   156.80 %
Vor Biopharma Inc   154.23 %
Glucotrack Inc   151.40 %
Capforce Inc   141.40 %
Protagenic Therapeutics Inc new  137.58 %
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %

Date modified: 2026-09-08T22:05:12+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.